Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
16.41
-0.38 (-2.26%)
Jan 21, 2025, 4:00 PM EST - Market closed
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $41.67M in the quarter ending September 30, 2024, a decrease of -7.68%. This brings the company's revenue in the last twelve months to $160.40M, down -45.85% year-over-year. In the year 2023, Arcturus Therapeutics Holdings had annual revenue of $166.80M, down -19.03%.
Revenue (ttm)
$160.40M
Revenue Growth
-45.85%
P/S Ratio
2.82
Revenue / Employee
$891,106
Employees
180
Market Cap
444.50M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ARCT News
- 11 days ago - Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial - Business Wire
- 15 days ago - Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
- 5 weeks ago - Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 2 months ago - Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Business Wire
- 2 months ago - Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data - Seeking Alpha
- 2 months ago - Meiji Seika Pharma Announces Investment in ARCALIS, Inc. - Business Wire
- 2 months ago - Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Business Wire